SUMMARY Patients with methylmalonic aciduria have an excessive intramitochondrial accumulation of acylcoenzyme A compounds that may reduce the availability of free coenzyme A (CoA) for normal metabolic requirements, producing profound metabolic disturbances. Giving carnitine to a patient with methylmalonic aciduria produced an increase in hippurate excretion (an index of intramitochondrial adenosine triphosphate (ATP) and CoA availability), a large increase in short chain urinary acylcarnitines, and a reduction in excretion of methylmalonate and methylcitrate. These acylcarnitines were shown by fast atom bombardment and B/E linked scan mass spectrometry to be propionylcarnitine and acetylcarnitine. Carnitine acts by removing (detoxifying) propionyl groups, thereby releasing CoA and restoring ATP biosynthesis and concentrations towards normal. L-carnitine may play a central role in maintenance of mitochondrial and cellular homoeostasis in methylmalonic aciduria and propionic acidaemia. These principles may provide an approach to the treatment of this and other disorders, inherited and acquired, in which accumulation of acyl CoA metabolites results in sequestration of free CoA, thereby perturbing metabolic homoeostasis.
Recent reports indicate the potential need for supplementary carnitine in patients with several disorders of intermediary metabolism, particularly those associated with the organic acidurias.1-3 Many of these latter disorders are associated with the accumulation of short chain acylcarnitines (Chalmers, Roe, Hoppel, and Stacey, unpublished data). Carnitine was administered to a child with methylmalonic aciduria because of the clinical benefit seen after giving L-carnitine to another patientwithpropionicacidaemia.Propionicacidaemia and methylmalonic aciduria have in common the accumulation of propionyl coenzyme A (CoA) and its metabolites, with their untoward metabolic effects. We believe that there is an increased carnitine requirement in methylmalonic aciduria, we detail the beneficial effects on intermediary metabolism after giving carnitine, and identify acylcarnitines excreted in large quantities after carnitine supplementation. This study supports a role for carnitine in the management of patients with this disorder and those with propionic acidaemia. This study was approved by the ethical committee of Northwick Park Hospital and the Clinical Research Centre, Harrow.
Clinical description
The patient, a girl, was the first child of unrelated caucasian parents. After a normal pregnancy, delivery at term was complicated by breech presentation requiring caesarean section. She was breastfed initially, but on day three of life she became tachypnoeic and hypotonic, and proceeded into coma with profound metabolic acidosis (base deficit, 21 mmol/l). Gasliquid chromatography of her urine and blood plasma followed by mass spectrometry gave a diagnosis of methylmalonic aciduria, and this was confirmed by enzymology on cultured skin fibroblasts. Attempts to treat with 916 
Methods
Urinary organic acids were quantitatively extracted using DEAE-Sephadex and established procedures,4 and they were analysed by capillary gas chromatography of their trimethylsilyl (TMS) and TMSethoxime derivatives on 25 m fused silica columns coated with a non-polar chemically bonded polymethylsiloxane (CP-SIL-5, Chrompak, UK London).
A split injection (70:1) of 2 Vu1 sample at 200°C was temperature programmed at 6°C/min from 70°-250°C. The carrier gas was helium, 1-4 ml/min. Components were identified using retention indices, and quantified using n-tetracosane as a standard. Identifications were subsequently confirmed using capillary gas chromatography mass spectrometry.
Plasma and urinary carnitine and acylcarnitines were determined by radioenzymatic assay utilising [1-14C]-acetyl-CoA and carnitine acetyltransferase, according to the method of Brass and Hoppel.5 Acylcarnitines in plasma were separated into an acid soluble fraction (short chain acylcarnitines) and an acid insoluble fraction (long chain acylcarnitines). The results are expressed in ,umol/l for plasma and nmol/mg creatinine for urine.
Acetylcarnitine and propionylcarnitine were synthesised according to the method of Bohmer and Bremer,6 using the acylchlorides and L-carnitine under reflux conditions followed by multiple recrystallisations. Aqueous eluates from urine samples passed over Dowex-1 colums at neutrality7 and concentrated by lyophilisation were analysed by fast atom bombardment (FAB) mass spectrometry,8 using xenon gas and samples in a glycerol matrix with a VG 7070 HS mass spectrometer. Acylcarnitines were further analysed by linked scanning at constant B/E ratios that provided an independent fragmentation pattern for each major ion in the mass spectrum.9
At the time of the study, although requiring nasogastric tube feeding, the child was under reasonably good metabolic control as shown by normal plasma glucose, ammonia, electrolyte, acid base status, and by urinary organic acids. D, L-camitine, 12.4 mmol (200 mg/kg body weight) was given as a single oral dose representing 100 mg/kg of the L-isomer (the isomer measured in the radioenzymatic assay).
Results
Before being given supplementary carnitine the child's plasma showed a total carnitine of 53.2 ,umol/l (normal, mean (SD) 46 1 (10X0) l,mol/l), free carnitine 35.8 F±mol/l (normal, mean (SD) 36.7 (7.6) ,umol/l), acid soluble (short chain) acylcarnitines 17.1 ,umol/l (normal, mean (SD) 5.7 (3.5) ,umol/1), and acid insoluble (long chain) acylcarnitines 0 3 t±mol/l (normal, mean (SD) 3 .7 (1*5) ,umol/l).10 These results show normal plasma free carnitine values but considerably raised short chain acylcarnitines.
In the urine, free carnitine was 142 nmol/mg creatinine (normal, mean (SD) 51.3 (40-1) nmol/mg creatinine) and combined acylcarnitines were 352 nmol/mg creatinine (normal, mean (SD) 73.7 (39.5) nmol/mg creatinine), giving a total urinary carnitine of 494 nmol/mg creatinine (normal, mean (SD) 125.1 (74.7) nmol/mg creatinine). The urine therefore showed increased excretion of both free carnitine and acylcarnitines.
After giving carnitine, urine samples were collected sequentially over a 24 hour period for organic acid analysis and acylcarnitine measurements. During this period, 476 ,umol of carnitine, as free and acylcarnitines, were excreted in the urine. This amount represented 8-1 % of the ingested dose.
The total carnitines excreted comprised 269 [±mol free and 207 ,umol acylcarnitines. Urinary free carnitine excretion paralleled acylcarnitine excretion throughout the study period. Most of the excretion 77.2 %-occurred in the first 12 hours.
Although there were no notable fluctuations in other metabolites, there were major changes in urinary hippurate, methylmalonate, methylcitrate, and acylcarnitines during the first 12 hours (Fig. 1) . There was a rapid 6 fold increase in hippurate concentration at 30 minutes after the dose, with apeak value attained at 3 hours, and the values decreasing thereafter. In contrast, there was a less than twofold increase in acylcarnitine excretion by 30 
Hours after carnitine (Fig 2(a) ). The Further evidence for the presence of propionylcarnitine and acetylcarnitine was provided by linked scanning at a constant B/E ratio9 that produces an independent fragmentation pattern for each major ion in a mass spectrum. The constant B/E linked scan spectra for the m/z 218 ions from synthetic propionylcarnitine and the urine extract are compared in Fig. 2(b) and (c) , respectively. Similarly, comparison of the linked scan spectra of synthetic acetylcarnitine, m/z 204, and that ion in the urine are shown in Fig. 2(d) and (e), respectively. The similarities in these linked scans between the synthesised acylcarnitines and those excreted by the patient seem identical. In each case the characteristic loss of 59 daltons corresponding to (CH3)3N is seen. The m/z 218 produces the m/z 159 from propionylcarnitine while the m/z 204 yields the m/z 145 from acetylcarnitine. Discussion Carnitine supplementation in this child with methylmalonic aciduria was considered because of the beneficial clinical and metabolic effects noted after carnitine was given to another patient with propionic acidaemia.1 Both propionic acidaemia and methylmalonic aciduria are disorders associated with the accumulation of acyl CoA compounds inside the mitochondria. Most Thus the majorproblems in methylmalonic aciduria and propionic acidaemia are: (a) lack of availability of CoA, (b) diminished ATP production, and (c) insufficient L-carnitine for the patients' increased metabolic requirements. All of these are caused by the accumulation of propionyl CoA. Since we have shown that propionyl groups can be detoxified and eliminated in the urine as propionylcarnitine, we propose the use of supplementary L-carnitine in the long term management of these diseases. With adequate supplementary L-carnitine, a mechanism is provided whereby flux of propionylcarnitine (formation and excretion) may be made to equal the excess accumulation of propionyl CoA when dietary protein intake is only moderately restricted. These principles may apply to the treatment of a wide group of disorders-some inherited, such as the organic acidurias and some acquired, such as Reye's syndrome21-in all of which accumulation of various acyl CoA metabolites results in the sequestration of CoA, thereby perturbing metabolic homoeostasis.
